

## VIDAS®TB-IGRA

**FULLY AUTOMATED TESTING SOLUTION** 



### Did you know?

## LATENT TUBERCULOSIS, A HUGE RESERVOIR FOR A DEADLY DISEASE

### Tuberculosis (TB):

one of the top deadliest infectious disease worldwide

**1/4** of people worldwide are infected with latent TB

Without treatment. 10-15% of them are at risk to develop active TB disease



#### DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION (LTBI)


A priority to: • Prevent the development of TB disease

• Stop the spread of TB

#### CURRENT TB-IGRA TESTS ARE CUMBERSOME

SEVERAL STEPS & TUBES NO GOLD STANDARD

HANDS-ON-TIME



## VIDAS® TB-IGRA

#### **RELIABLE RESULTS FOR TB INFECTION**

## **MORE CONFIDENCE** IN IDENTIFYING INFECTED PEOPLE



## HIGH SENSITIVITY ON ACTIVE TB POPULATION\*

**VIDAS® TB-IGRA sensitivity** 

**97.5%** vs. **80.7%** for QFT®-Plus

**VIDAS® TB-IGRA specificity** 

The VIDAS® TB-IGRA assay gave

- more true-positive results,
- fewer false-negative results, than the comparative assay.



#### **HIGH SPECIFICITY**

ON POPULATION AT EXTREMELY LOW LEVEL OF TB INFECTION\*\*

**VIDAS® TB-IGRA specificity** 

**97.6%** vs. **95.2%** for QFT<sup>®</sup>Plus



**High capacity** to identify active TB patients and non-TB-infected patients



## **STRONG AGREEMENT WITH COMPARABLE SOLUTION**\*\*\* ON POPULATION WITH MIXED RISK OF TB INFECTION

92.1% VIDAS® Positive Percent Agreement (PPA)


90.1% VIDAS Negative Percent Agrement (NPA)

As there is no gold standard for the diagnosis of individuals with Latent TB Infection (LTBI), PPA and NPA with a comparative assay were determined.

<sup>\*</sup> Evaluated on culture-confirmed active TB patients excluding indeterminate results

<sup>\*\*</sup> Blood donors from a low endemic country considered at extremely low risk of TB infection \*\*\* Compared to QuantiFERON®-TB Gold Plus test (QFT®-Plus)

#### FOR IMPROVED PATIENT MANAGEMENT



Detect more TB-infected individuals as risk becomes higher

Globally the rate of positive results was statistically higher ( $\alpha$ =5%) for the VIDAS® TB-IGRA assay than for the QFT®-Plus assay (p-value < 0.0001).

As the TB-exposure risk increases, VIDAS® TB-IGRA detects more positive samples reflecting a stronger association with the expected likelihood of Latent TB Infection\*\*\*.

# REDUCE CHALLENGES LINKED TO INDETERMINATE RESULTS

Analysis on indeterminate results

VIDAS®TB-IGRA		QF I®-Plus
Indeterminate	0.1%	1.2%
	(2/1660)	(20/1660)

VIDAS® TB-IGRA assay provides fewer indeterminate results\*\*\*: high capacity to give valid, interpreted results to clinicians.

The rate of indeterminate results was statistically lower ( $\alpha$ =5%) for the VIDAS® TB-IGRA assay than for the QFT®-Plus assay (p-value = 0.0001).




Reliable results for TB infection, greater ability to detect Mycobacterium tuberculosis infected persons

## VIDAS® TB-IGRA

#### **FULLY AUTOMATED SOLUTION**

### **OPTIMIZE YOUR WORKFLOW**

ALL STEPS MANAGED INSIDE THE VIDAS® 3 from a single whole blood tube



#### **EASY TB-IGRA TESTING SOLUTION**

- No multiple tubes to handle
- No sample preparation
- Simply load & go

#### **GOOD ANALYTICAL PRECISION\***

 The repeatability estimates (CV%) < 10.0%</li>

# TAKE CONTROL OF YOUR TB-IGRA testing with VIDAS® 3

- MINIMAL HANDS-ON-TIME Easy to use, simple process
- QUICK TIME TO RESULT Results available in 1 day
- COST-EFFECTIVE

  All materials included in the kit (calibration, controls)








## **AVAILABLE** ON VIDAS® 3

### BECAUSE IT MAKES SENSE ON VIDAS®

Easily manage TB testing within your activity











	VIDAS® TB-IGRA	VIDAS® IFNg QC PANEL
Reference	423111	424069
Tests / kit	20 TB-IGRA tests 3 strips/SPR for 1 Patient test	N/A
Kit content	60 strips and 60 SPR S1, C1 Stimulation reagents	4 lyophilized vials (4x3 mL) 2 x IFNg QC1 x 3 mL 2 x IFNg QC2 x 3mL
Time to result	17h for 1 patient	43 min
Sample type	Whole blood (lithium heparin tube)	lyophilized recombinant human IFN-γ
Sample volume	300 µL x 3 (for the 3 strips)	150 μL
Calibration frequency	56 days	
<b>.</b>		

43 minutes

#### REFERENCES

Calibration protocol

- 1. https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
- 2. https://www.ecdc.europa.eu/en/tuberculosis. 3. VIDAS®TB-IGRA (Ref : 423111) Package insert 053331
- Clinical Trials.

โฆษณาโดยตรงต่อผู้ประกอบวิชาชีพทางการแพทย์ และสาธารณสุขที่ได้รับการยกเว้นโดยไม่ต้องขออนุญาต



03-24 932647 008/GB/C/ This document is not legally binding, bioMérieux reserves the right to modify specifications without notice / BIOMÉRIEUX (egg. PIONEERING DIAGNOSTICS and VIDAS are used, pending and/or registered trademarks belonging to bioMérieux or one of its subsidiaries or one of its companies. Any other name or trademark is the property of its respective owner / bioMérieux S.A. RCS tyon 673 620 399 / Protos: Getty Images, Garret, Bouchut / Printed in France / Fano / 537 519 449 RCS Lyon: Do not little

i+MED Laboratories Co., Ltd.

240 Ayothaya Tower, Room No. 240/2,240/41, Floor 1,20, Ratchadaphisek Road, Huai Khwang Subdistrict, Huai Khwang District, Bangkok 10310









